Expression of Interleukin-1 and Temporomandibular Disorder: Contemporary Review of the Literature by Sorenson, Adam et al.
Marquette University
e-Publications@Marquette
School of Dentistry Faculty Research and
Publications Dentistry, School of
1-1-2017
Expression of Interleukin-1 and
Temporomandibular Disorder: Contemporary
Review of the Literature
Adam Sorenson
Marquette University
Kyle Hresko
Marquette University
Seth Butcher
Marquette University
Sean Pierce
University of California - Los Angeles
Vinícius Augusto Tramontina
Pontifical University of Paraná
See next page for additional authors
Accepted version. CRANIO®: The Journal of Craniomandibular & Sleep Practice, (2017). DOI. © 2017
Taylor & Francis. Used with permission.
Authors
Adam Sorenson, Kyle Hresko, Seth Butcher, Sean Pierce, Vinícius Augusto Tramontina, Rosalia Leonardi,
Carla Loreto, Jose A. Bosio, and Luis Eduardo Almeida
This article is available at e-Publications@Marquette: https://epublications.marquette.edu/dentistry_fac/297
  
 
   
 
   
   
 
   
   
    
   
 
   
 
 
  
 
  
  
 
  
  
 
 
  
 
  
  
Marquette University
e-Publications@Marquette
Dentistry Faculty Research and Publications/School of Dentistry
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript.
The published version may be accessed by following the link in the citation below.
CRANIO®: The Journal of Craniomandibular & Sleep Practice, (2017). DOI. This article is © Taylor 
& Francis and permission has been granted for this version to appear in e-
Publications@Marquette. Taylor & Francis does not grant permission for this article to be
further copied/distributed or hosted elsewhere without the express permission from Taylor &
Francis.
Expression of Interleukin-1 and 
Temporomandibular Disorder: 
Contemporary Review of the Literature
Adam Sorenson
Surgical Sciences Department, Oral Surgery, School of Dentistry, Marquette University,
Milwaukee, WI
Kyle Hresko
Surgical Sciences Department, Oral Surgery, School of Dentistry, Marquette University,
Milwaukee, WI
Seth Butcher
Surgical Sciences Department, Oral Surgery, School of Dentistry, Marquette University,
Milwaukee, WI
Sean Pierce
OMFS Department, School of Dentistry, University of California, Los Angeles, Los Angeles, CA
Vinicius Tramontina
Periodontic Department, School of Dentistry, Pontifica Universidade Catolica do Parana, Brazil
Rosalia Leonardi
  
 
  
 
  
  
  
 
 
     
  
     
       
    
    
 
    
   
 
   
 
  
 
    
 
       
    
    
     
     
   
   
   
     
    
 
     
    
   
  
Orthodontic Department, School of Dentistry, Catania University, Italy
Carla Loreto
Anatomy Department, School of Medicine, Catania University, Italy
Jose Bosio
Orthodontic Department, School of Dentistry, University of Maryland, Baltimore, MD
Luis Eduardo Almeida
Surgical Sciences Department, Oral Surgery, School of Dentistry, Marquette University,
Milwaukee, WI
Abstract
Objective: Temporomandibular disorders (TMD) are a group of conditions affecting the
temporomandibular joint (TMJ), leading to jaw dysfunction, joint and muscle pain, and a decrease in
quality of life. A communication network of pro- and anti-inflammatory mediators called cytokines
maintains the homeostasis of the TMJ. This review will focus on the Interleukin (IL) family of cytokines,
which have been quantified in TMJ synovial fluids in a variety of studies. IL-1α and IL-1β have pro-
inflammatory effects, while the endogenous receptor antagonist (IL-1RA) inhibits the pro-inflammatory
effects of IL-1.
Methods: A literature search (2006–2016) to identify eligible studies was completed using the PubMed
database. Studies identified used saline irrigation to quantify cytokine profiles in synovial fluid of healthy
and/or dysfunctional joints.
Results: The initial search yielded 111 articles, 5 of which met the inclusion criteria after inter-reviewer 
discussion.
Conclusions: Articles that compared IL-1 concentrations in TMD vs. control groups found significant
differences.
Keywords: Temporomandibular joint, Interleukin-1, temporomandibular joint disorder
Introduction
The temporomandibular joint (TMJ) is one of the most complex articulations in the human body. The
TMJ is an intricate joint that is made up of the joint itself, the masticatory muscles, cartilaginous tissue,
and bone. Temporomandibular disorders (TMD) are a group of conditions affecting the TMJ. These 
disorders lead to jaw dysfunction, joint and muscle pain, and a decrease in overall quality of life.1 There 
is a variable disease progression from mild inflammatory responses to complete architectural changes of 
the TMJ. Along with the different stages of TMD, there are different signs and symptoms that
accompany each stage. This is the result of adaptation and remodeling of the TMJ. When the disc is
overloaded and it exceeds its remodeling capacity, it may suffer structural changes. The pathogenesis of 
TMD is multifactorial, but the early identification of the major contributing factor is critical for improved
treatment outcomes. Of the TMJ dysfunctions that may lead to disc degeneration, disc displacement is
generally seen to precede osseous remodeling, disc perforation and osteoarthritic changes.2 
The TMJ is subjected to constant stress, due to significant forces exerted during function. Because of
this, constant remodeling of the joint is necessary with simultaneous metabolism and repair. Excessive
loading on the TMJ is generally considered an initiating pathogenesis of TMD. This constant remodeling
is the result of a dynamic and extremely complex communication between the cells that make up the
    
      
   
  
    
   
  
    
     
    
 
 
   
 
   
     
 
 
     
     
  
     
   
 
    
    
   
 
    
   
  
 
  
    
     
    
    
   
  
 
  
     
  
      
   
    
   
  
TMJ, specifically the cells of the synovial joint, the articular disc, and the condylar cartilage.3 
Homeostasis of the TMJ is maintained through a complex network of cellular molecules, such as
cytokines, proteinases, and other inflammatory mediators. These regulatory molecules affect the
metabolism of the extracellular matrix by altering gene and protein expression. There have been wide
arrays of cellular markers studied in TMD. These include inflammatory mediators such as the Interleukin
family, matrix metallo-proteinases, bone-destruction associated cytokines, apoptotic mediators, and
anti-inflammatory cytokines.4 Most of these studies have found correlations between a specific
homeostasis mediator and a stage in TMD development. Unfortunately, due to the nature of the TMJ
and current treatment, most studies have been limited to synovial fluid examination of these markers.
Thus, a more complete marker profile is needed to gain a better understanding of the pathology of
TMD.
Cytokine is a general name for small proteins produced and released by cells for communication.
Cytokines are responsible for initiating, maintaining, and halting inflammatory processes. As such, there 
is a wide array of cytokine families that are responsible for different functions in different areas of the
body.5 This review will examine the role of the Interleukin-1 (IL-1) family of cytokines in TMD initiation
and progression.
The most numerous and complex family of cytokines is the Interleukins.6 A great amount of effort has
been spent on mapping out and understanding the interactions of the Interleukin network. Within this
family, there are both pro-inflammatory and anti-inflammatory mediators. The prevalence of specific
Interleukins varies, and this correlates to their degree of influence on cellular activity. Their subsequent
expression triggers a cascade of events, and IL-1 is the prime example of this.
The IL-1 system includes at least 21 different molecules. These molecules make up the IL-1 receptors,
co-receptors, ligands and endogenous antagonists. The IL-1 family consists of three types of ligands: IL-
1α and IL-1β both have pro-inflammatory effects, while IL-1 receptor antagonist (IL-1RA) inhibits their 
pro-inflammatory functions by acting as a competitive receptor inhibitor. There are also two different
receptors that make up the IL-1 family, Type 1 and Type 2 IL-1 receptors. Type 1 IL-1 receptor is
responsible for induction of intracellular signal transductions after binding with IL-1. Type 2 IL-1 receptor
acts as a decoy receptor. Its function is to bind to IL-1 without producing any effects, thus reducing the
overall availability of IL-1 to bind and initiate an inflammatory response. Additionally, Type 2 IL-1 
receptor can be released from the cell surface in a soluble form that can bind to IL-1 ligands to inactivate
them before they can produce a pro-inflammatory response.7 The intricate balance of the IL-1 family
molecules and receptors has a profound effect on the homeostasis of the TMJ. Many studies have
indicated that higher levels of IL-1α and IL-1β are present in the synovial fluid of patients suffering from
TMD.8,9 These studies have taken synovial fluid samples from patients suffering from TMD at different
stages. Conclusions have been made suggesting that elevated levels of these cytokines contribute to the 
initiation and progression of TMD.
In normal, healthy TMJ discs, there are virtually no pro-inflammatory cytokines present.9 Soon after TMJ
discs are subjected to excessive loads and function, they begin to undergo pathologic changes. These
mechanical disturbances produce an imbalance between anabolic and catabolic processes, which
progressively alters TMJ disc tissue.10 Damage of the TMJ disc is associated with excessive catabolic
activity that results from cytokines and proteases. IL-1 is one of the most prevalent and first cytokines
produced as a response to excessive loading of the TMJ.11 The release of IL-1 initiates a cascade of 
events that ultimately leads to tissue alteration. This cascade alters the extracellular matrix by depleting
matrix substances such as collagen.
 
   
     
    
 
  
 
    
  
  
 
    
    
      
    
   
      
    
     
   
 
 
 
 
 
  
   
  
   
  
     
  
  
  
  
 
   
   
      
      
  
  
 
 
  
Although the role of IL-1 in inflammation and TMJ dysfunction is well known, previous studies have 
investigated the presence of IL-1 in animal models, cadavers, or synovial fluid of humans. The goal of 
this review is to examine IL-1 levels in human synovial fluid and disc studies that compare healthy and
diseased TMJs.
Materials and methods
Search strategy
Two reviewers conducted an electronic literature search using the PubMed database. Inclusion criteria
were articles written in English published in the last 10 years (2006–2016) with human subjects. The
following search strategies were used:
1. “Osteoarthritis” [MeSH Terms] OR “arthritis, rheumatoid” [MeSH
Terms] AND “temporomandibular joint disorders” [MeSH Terms] OR“temporomandibular joint”
[MeSH Terms] AND “Interleukin-1” [MeSH Terms] AND “2006/05/18” [PDat] : “2016/05/14”
[PDat] AND “humans” [MeSH Terms]
2. “Temporomandibular joint disorders” [MeSH Terms] OR“temporomandibular” [All 
Fields] AND “physiopathology” [Subheading] OR “joints” [All Fields] OR “joint” [All 
Fields] AND “temporomandibular” [All Fields] OR “degeneration” [All 
Fields] AND “temporomandibular” [All Fields] OR “temporomandibular joint” [MeSH
Terms] AND“Interleukin-1” [MeSH Terms]
Reviewers independently removed duplicates and screened titles. Inclusion and exclusion criteria were 
applied during an independent abstract analysis. Inter-reviewer discussion completed the selection
process.
Selection criteria
Eligible studies met the following inclusion criteria:
1. Studies evaluating IL-1 presence or concentration in synovial fluid or discs of dysfunctional 
and/or healthy TMJs
2. Articles written in English
3. Human studies
4. Publications in the last ten years (2006–2016)
Exclusion criteria included:
1. Case reports
2. Pilot studies
3. Literature reviews
Data analysis
Study designs and parameters varied greatly; thus data analysis was not practical. Some studies directly
compared cytokine profiles in healthy and dysfunctional joints. Others quantified cytokines solely in
healthy or diseased joints. The following parameters were gathered from the selected articles:
author/year of publication, sample studied, mean age of subjects, Interleukins evaluated, method of
TMJ assessment, and a summary of the results (Table 1). All studies utilized immunoassay for the
Interleukin assessment. This paper will discuss results pertaining to IL-1, though selected articles
examined additional Interleukins.
   
 
 
 
    
     
   
 
 
 
 
     
   
  
   
   
    
   
    
     
 
      
      
  
   
    
   
  
 
     
    
  
   
    
 
 
  
o r/ year Sample Age 
(mean) 
Ahmed et al., Gl : 22 rheumatoid arthrit is patients with or Unreported 
2014 witho ut TMD 
Hamada et Gl : successfu l (s-), cl inical success after joint 46.S 
al., 2006 irrigat ion (25 patients) 
4 1.1 
Inte rleuk in 
Il-lra , Il -l sRII 
IL-113, Il -6, Il-8, Il- 12p70, Il-10 
IL- l o, JL-113, IL-2, IL-3, IL-4, IL-5, IL-
6, IL·7, IL-8, Il·l0, IL- 12 
TMJ asses sme nt 
MRI, cl inica l signs 
and symptoms 
MRI, cl inica l signs 
and symptoms 
Results 
High IL-lra levels in rela ti on to TNF in TMJ synovial flu id 
correlated to greater degrees of condylar erosion 
Il-6: G2>Gl 
ll-10 : Gl >G2 
ll-1: no s ign ificant differences 
IL-113, IL-2, IL-6 , IL-8, Il-10 : Gl>G2 
IL-10, IL- 113, and IL-6 were mostly undetectable 
No s ingle cytokine was positive in a ll samples . IL- l o showed most 
abundant expression 
Table 1. Researchers’ characteristics and main results.
Results
General outcomes
The initial electronic search returned 111 records. Exclusion criteria were publications older than
10 years, non-human studies, and articles that did not compare IL-1 expression levels in a disease group
and control. Inter-reviewer discussion resulted in the exclusion of 106 articles. Five articles remained in
this review. Statistical analysis was not completed due to differing parameters, variables, and study
designs.
Description of the studies
Ahmed et al.12 investigated the association of Interleukin-1 (IL-1), tumor necrosis factor (TNF), and
autoantibodies to citrullinated proteins (ACPA) with radiological signs of TMJ disc displacement and
tissue resorption in rheumatoid arthritis (RA) patients. Twenty-two RA patients were included,
regardless of whether they had TMJ symptoms. TMJ synovial fluid was analyzed for the ratios of the
cytokines and their endogenous control mediators after saline washing of the joint. Magnetic resonance
imaging (MRI) of disc position was interpreted and presence of erosions and joints were grouped into
five categories: (1) normal, (2) disc displacement with reduction, (3) disc displacement without 
reduction, (4) indeterminate, and (5) disc not visible. Venous blood was collected for analysis. High IL-
1RA levels in relation to TNF in TMJ synovial fluid correlated to greater degrees of condylar erosion.
Hamada et al.13 examined concentrations of TNF-α, IL-1β, IL-6, IL-8, IL-12, and IL-10 in the irrigated
synovial fluid of patients with chronic closed lock (CCL) of the TMJ. Clinical outcome of the irrigation was
correlated to cytokine concentrations. Thirty-eight patients with CCL of the TMJ underwent saline 
irrigation of the superior joint compartment. Patients were divided into successful (s-) or unsuccessful
(u-) groups according to clinical success. Concentrations of IL-6 were significantly higher in the u- group,
and concentrations of IL-10 were significantly higher in the s- group. No significant differences in
detection and concentration were observed among the other cytokines tested, including IL-1.
Kim et al.14 compared cytokine profiles of TMJ synovial fluid of normal individuals and TMD patients.
Thirty-three TMJ patients were assigned to the control group and 22 patients seeking treatment for
TMD were assigned to the TMD group. Saline irrigation with synovial fluid collection was performed.
Concentrations of GM-CSF, INF-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-α were measured. GM-
CSF, INF-γ, IL-1β, IL-2, IL-6, IL-8, IL-10 and TNF-α were detected in the TMD group. No cytokines were 
detected in the control group. IL-1β, IL-6, and GM-CSF were the most frequently found cytokines in the 
TMD group. The authors concluded that there were significant differences in detection of the cytokines
with a higher level of IL-1β in the TMD group vs. the control group.
 
     
     
    
   
    
     
 
   
   
  
   
 
 
      
     
   
  
   
    
  
  
   
   
 
  
    
  
 
    
     
  
     
 
 
   
   
 
     
   
 
     
     
   
  
Kristensen et al.15 quantified the proinflammatory cytokines IL-1β, IL-2, IL-6, TNF, and IFN-γ in healthy
TMJ synovial fluid for comparison to TMJ pathologies. Twenty healthy, young participants were chosen
with no history of temporomandibular disease or dysfunction. Synovial fluid was collected from the
superior TMJ compartment bilaterally. Cytokines were quantified in 14 of the samples collected. Median
cytokine values in pg ML-1 were: TNF, 23; IL-2, 1.8; INF-γ, 10, IL-1β, IL-6, and IL-10 were considered
undetectable. A significant correlation was noted between TNF and IFN-γ concentrations.
Matsumodo et al.16 developed a comprehensive cytokine profile of 14 patients with TMD and correlated
the levels with radiological findings. No control group participated. Participants had verified anterior disc
displacements without reduction. Synovial fluid was collected and analyzed using Human Cytokine Array
V. No single cytokine was positive in all samples, but those present most abundantly were IL-1α, TGF-β2,
and VEGF.
Discussion
Studies differed in their designs, subject groups, and variables measured. Two of the five studies
selected (Ahmed, Kim) directly compared cytokine concentrations in both groups of TMD patients and
healthy controls. Both studies found significant differences in cytokine profiles, with Ahmed et al. finding
high IL-1RA levels correlating to greater degrees of condylar erosion and Kim et al. finding a higher level 
of IL-1β in the TMD group.12,14 Hamada et al. quantified cytokines during saline irrigation as a treatment 
for CCL of the TMJ, then divided subjects into groups based on clinical success. Though differences were
noted in other Interleukins, no significant differences in detection and concentration were noted for IL-
1.13 The two remaining studies lacked control groups. Kristensen et al. looked solely at cytokine 
concentrations in healthy TMJ synovial fluid and noted IL-1β was undetectable.15 Matsumodo et al.
examined cytokine profiles of patients with TMD and found IL-1α to be abundantly expressed.16 
Despite largely differing study designs, conclusions can be made regarding the association of IL-1 with
temporomandibular dysfunction. The IL-1 family of cytokines, including IL-1α, IL-1β, and IL-1RA, was 
generally found in higher concentrations in the synovial fluid of dysfunctional joints.12,14,16 
Limitations exist in the studies selected for this review. Study samples were small, ranging from 14 to 55
patients and were limited to synovial fluid. Natiella et al.17 emphasized that correlation of synovial fluid
aspirates with tissue findings is necessary for a more complete understanding of joint biochemistry.
Therefore, more reliable data would be obtained from cytokine studies of both joint aspirates and disc
samples.
A recent study by Almeida et al.18 was the first to use an immunohistochemical approach to quantify IL-
1β in human TMJ disc samples. The study concluded that IL-1β plays a role in the process leading to
TMD, citing a statistically significant difference between study groups. These results correlate with
synovial fluid aspirate findings in the studies selected in this review. Therefore, IL-1β can be found in
both the synovial fluid and the articular disc of the TMJ.
Conclusion
Continued synovial fluid and disc tissue studies of additional IL-1 family cytokines as well as other
markers will provide a more reliable and complete profile of inflammatory contributors to TMD. This
may ultimately provide a positive contribution to the future of TMD therapy. Knowledge of the markers
involved in inflammation and destruction of the TMJ opens possibilities for more targeted therapy.
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Pharmaceutical blockade of IL-1 activity has been used to successfully treat joint, bone, and muscle
diseases such as rheumatoid arthritis, erosive osteoarthritis, and traumatic joint injuries [19]. Specific
targeting of pathologic mediators, including the IL-1 family of cytokines, may significantly reduce
inflammation and prevent further degeneration of the TMJ.
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